



**Biocon Limited**  
20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

BIO/SECL/EA/2023-24/140

December 22, 2023

To The Manager, <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
<b>Scrip Code - 532523</b>	<b>Scrip Symbol - BIOCON</b>

**Subject: Press Release titled “Biocon Biologics Partners with Sandoz for the Distribution of “Adalimumab BS Subcutaneous Injection [FKB]” in Japan”**

Dear Sir/Madam,

Please find enclosed the press release titled **“Biocon Biologics Partners with Sandoz for the Distribution of “Adalimumab BS Subcutaneous Injection [FKB]” in Japan.”**

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

---

**Mayank Verma**  
**Company Secretary and Compliance Officer**  
**Membership No.: ACS 18776**

Encl: Press Release

## PRESS RELEASE

# Biocon Biologics Partners with Sandoz for the Distribution of “Adalimumab BS Subcutaneous Injection [FKB]” in Japan

**Bengaluru, India: December 22, 2023**

**Biocon Biologics Ltd (BBL)**, a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), signed today a Distribution Agreement with Sandoz, granting the Company the exclusive rights to promote, sell and distribute “Adalimumab BS for subcutaneous injection [FKB]”<sup>\*1</sup> in Japan. Based on this Agreement, Viartis has completed marketing and promotion of the product as of December 15, 2023, but will continue to provide transition support until Sandoz will gradually assume responsibilities for the product starting February 15, 2024.

Biocon Biologics has acquired the global biosimilars portfolio of Viartis including Adalimumab. Fujifilm Kyowa Kirin Biologics Co. Ltd., the developer of the drug, has concluded an exclusive global marketing license agreement with Biocon Biologics Ltd affiliate.

Adalimumab BS for subcutaneous injection [FKB] is a biosimilar of Humira® (generic name: adalimumab (genetical recombination)) and is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. Sandoz is committed to further strengthening its product pipeline to drive sustainable business growth. The transfer of the distribution rights of this product is part of this strategy, and its addition to the product portfolio will strengthen Sandoz's immunology and biosimilar portfolio.

Biocon Biologics [recently announced](#) the successful completion of its integration of the acquired Viartis' biosimilars business in 120 countries ahead of schedule, marking a significant milestone in the Company's journey as a fully integrated, global biosimilars enterprise. At a global level, Biocon Biologics has a robust pipeline of 20 assets for diabetology, oncology, immunology, and ophthalmology. Serving over 5.7M patients annually, the Company is committed to providing access to high-quality therapies and solutions to patients, healthcare systems and governments across the globe.

Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably across a range of areas including immunology, oncology, supportive care, and endocrinology. Since launching the first biosimilar in Europe in 2006, Sandoz has helped to create early and expanded patient access to life-altering medicines while increasing healthcare savings and creating competition that fuels further innovation. Sandoz aims to be the most trusted partner and will leverage its global track record and strengths to deliver high-quality medicines to the people of Japan promptly to ensure the sustainability of the Japanese healthcare system.

### Applicable Products

Product	Packing
Adalimumab BS Subcutaneous Injection 20mg Syringe 0.4mL [FKB]	1 syringe
Adalimumab BS Subcutaneous Injection 40mg Syringe 0.8mL [FKB]	1 syringe
Adalimumab BS Subcutaneous Injection 40mg Pen 0.8mL [FKB]	1 pen

\*1 Fujifilm Kyowa Kirin Biologics Co. Ltd. is a Marketing Authorization Holder in Japan.

### About Biocon Biologics Limited:

**Biocon Biologics Ltd. (BBL)**, a subsidiary of Biocon Ltd., is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives by enabling affordable access to high quality biosimilars for millions of patients worldwide. It is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. BBL has acquired the global biosimilars business of its long-standing partner Viatrix, which is a historic milestone in its value creation journey. Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. The Company has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. It has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, BBL is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website: [www.bioconbiologics.com](http://www.bioconbiologics.com); Follow us on Twitter/X: [@BioconBiologics](https://twitter.com/BioconBiologics) and LinkedIn: [Biocon Biologics](https://www.linkedin.com/company/biocon-biologics) for company updates.

**Biocon Limited**, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: [www.biocon.com](http://www.biocon.com); Follow-us on Twitter: [@bioconlimited](https://twitter.com/bioconlimited) for company updates.

For More Information:	
MEDIA: Biocon Biologics	INVESTORS
<p><b>Seema Ahuja</b> Global Head of Corporate Brand &amp; Head of Communications -EMs +91 99723 17792 <a href="mailto:seema.ahuja@biocon.com">seema.ahuja@biocon.com</a></p> <p><b>Stephanie Wasco</b> Head of Communications – Advanced Markets +1 203 343 4784 <a href="mailto:stephanie.wasco@biocon.com">stephanie.wasco@biocon.com</a></p>	<p><b>Nikunj Mall</b> Head, Investor Relations, Biocon Biologics +91 998 777 4078 <a href="mailto:nikunj.mall@biocon.com">nikunj.mall@biocon.com</a></p> <p><b>Saurabh Paliwal</b> Head - Investor Relations Biocon +91 95383 80801 <a href="mailto:saurabh.paliwal@biocon.com">saurabh.paliwal@biocon.com</a></p>